Compare ZLAB & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | ASH |
|---|---|---|
| Founded | 2013 | 1924 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2017 | 2016 |
| Metric | ZLAB | ASH |
|---|---|---|
| Price | $25.52 | $73.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $49.60 | ★ $65.57 |
| AVG Volume (30 Days) | ★ 983.0K | 799.2K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.38% |
| EPS Growth | ★ 38.46 | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | $460,156,000.00 | ★ $1,824,000,000.00 |
| Revenue This Year | $9.75 | $2.58 |
| Revenue Next Year | $26.03 | $4.28 |
| P/E Ratio | ★ N/A | $172.49 |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $46.30 |
| 52 Week High | $35.45 | $78.25 |
| Indicator | ZLAB | ASH |
|---|---|---|
| Relative Strength Index (RSI) | 73.93 | 56.46 |
| Support Level | $16.98 | $58.70 |
| Resistance Level | $26.66 | $74.99 |
| Average True Range (ATR) | 1.18 | 2.18 |
| MACD | 0.57 | -0.21 |
| Stochastic Oscillator | 87.07 | 26.37 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.